Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.47 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918822 | 1.00 | POLB (1.00) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL12408155 | 0.98 | POLB (0.96) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL1706504 | 0.91 | — | — | |
| SCHEMBL14204046 | 0.74 | POLB (0.59) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL25099331 | 0.74 | POLB (0.58) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL14030255 | 0.74 | POLB (0.58) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL22484889 | 0.74 | POLB (0.58) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL22485313 | 0.74 | POLB (0.58) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL11914610 | 0.74 | POLB (0.58) | POLBHPGDALDH1A1HTTHSD11B1 | |
| SCHEMBL14048244 | 0.74 | POLB (0.58) | POLBHPGDKDM4EMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3572412-B1 | PYRIDINE DERIVATIVE AS ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-01 | — | — | US | disclosed |
| US-8557841-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152262-A1 | VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE | ACOT7, LYPLA2, PPT1 | POLB 2398/4885HPGD 1461/4885ALDH1A1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.